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Abstract
Background: In type 1 diabetes (T1D), a prototypic autoimmune disease, effector T cells destroy beta cells. Normally,
CD4
+CD25
+high, or natural regulatory T cells (Tregs), counter this assault. In autoimmunity, the failure to suppress
CD4
+CD25
low T cells is important for disease development. However, both Treg dysfunction and hyperactive responder T-
cell proliferation contribute to disease.
Methods/Principal Findings: We investigated human CD4
+CD25
low T cells and compared them to CD4
+CD25
- T cells in
otherwise equivalent in vitro proliferative conditions. We then asked whether these differences in suppression are
exacerbated in T1D. In both single and co-culture with Tregs, the CD4
+CD25
low T cells divided more rapidly than CD4
+CD25
-
T cells, which manifests as increased proliferation/reduced suppression. Time-course experiments showed that this
difference could be explained by higher IL-2 production from CD4+CD25
low compared to CD4+CD25- T cells. There was also
a significant increase in CD4+CD25
low T-cell proliferation compared to CD4+CD25- T cells during suppression assays from
RO T1D and at-risk subjects (n=28, p=0.015 and p=0.024 respectively).
Conclusions/Significance: The in vitro dual suppression assays proposed here could highlight the impaired sensitivity of
certain responder T cells to the suppressive effect of Tregs in human autoimmune diseases.
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Introduction
The immune system of a healthy organism maintains immune
balance between tolerance and active response. Under normal
physiological conditions, the immune balance is a tightly regulated
network of several types of immune cells. If this is perturbed, the
response can be either inefficient (as in cancer) or, conversely,
over-reactive, resulting in conditions such as autoimmunity.
Maintaining peripheral self-tolerance by reducing effector T cell
function (suppression) is crucial in preventing autoimmunity.
Several mechanisms have been proposed, including induction of
T-cell anergy, immunological ignorance and control of the
expression of co-stimulatory molecules necessary for activation of
naı ¨ve, autoreactive T cells. In addition, regulatory T cells impart
direct suppression of effector function of autoaggressive T cells [1].
One regulatory subset that has been well characterized, expresses
cell-surface IL-2Ra-chains (CD25) constitutively [2]. Adoptive
transfer of these CD4
+CD25
high regulatory T cells (Tregs) in
animal models has been shown to offer protection from several
autoimmune diseases [3,4,5]. Thus, Tregs are highly specialized
cells that play a pivotal role in the control of autoimmunity.
In human subjects 1–3% of the CD4
+ T cell population
expressing the highest levels of surface CD25 demonstrates
regulatory properties [6]. These cells constitutively express
CD25 and Foxp3 and show increased expression of CTLA-4,
HLA DR, GITR and CD45RO, among other markers, although
it has been proven recently that resting nTregs express CD45RA
[7]. However, these surface markers are also expressed by
activated T cells. Tregs differ from activated T cells by decreased
expression of CD127 [8], which somewhat increases confidence in
the isolation of Tregs and in their enumeration. Nevertheless, a
population of CD4+CD25+CD127
low/- T cells does not exhibit
enhanced suppressor function compared to CD4+CD25
high T cells
in our hands (Glisic S, unpublished) as well as in studies of Miyara
et al [7]. Therefore, the unique property so far known to
distinguish Tregs from non-Tregs is their capacity to suppress
proliferation of other T cells. Suppression assays can be performed
both in vivo [9] and in vitro, the latter being the only option for
human studies. The in vitro assay usually involves responder T cells,
antigen-presenting cells (APC) and Tregs. Although our under-
standing of suppression is increasing [10], the exact relationship
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15154between cells in a suppression assay (both in vivo and in vitro) has not
been completely understood. A functional defect of Tregs was
reported inmanyautoimmune diseases (AD): SLE[11],rheumatoid
arthritis (RA) [12], multiple sclerosis [13] and type 1 diabetes [14].
However, evidence is emerging that Treg dysfunction cannot fully
explain decreased suppression of responder T cell proliferation in
AD. Recent reports showed that impaired sensitivity of responder T
cells (including autoreactive cells) to suppression by Tregs led to a
defective suppression of their proliferation in disease state in NOD
mice and human subjects with SLE and T1D [15,16,17]. The
importance of the presence of antigen-presenting cells (APC) in in
vitro suppression assay was also recently shown [18]. This report
suggested that APCs could be a major source of defects in
suppression in T1D. Other reports proved the important role of
co-stimulatory ligands on APC (CD28:B7, 4-1BB:4-IBBL,
ICOS:CD275, CD40:CD40L) which promote proper stimulation
of T cells, and, hence, suppression of responders’ proliferation
[19,20,21]. In addition, the type and strength of stimulation used in
an in vitro suppression assay is known to affect suppression in both
healthy and diseased states [6,22].
Such variability in the human suppression assay prompted us to
perform a comprehensive study investigating the aforementioned
factors. After we found the optimal in vitro conditions using cells
isolated from human leukopacks (enriched leukocytes from whole
blood) obtained from anonymous donors, we performed a study
involving T1D-related subject groups to test the hypothesis that
Tregs cannot suppress two different responder T cell subsets
equally well (CD4+CD25- and CD4+CD25
low). We expected the
difference in suppressive potential on the two cell subsets to be
amplified in subjects affected with or at risk to develop T1D
compared to control subjects.
Results generated in this study suggest that (i) the type of the
responder T cells set up in an in vitro suppression assay has the
greatest impact on suppression by Tregs (ii) CD4
+CD25
low T cells
divide more than CD4
+CD25
- T cells and are more difficult to
suppress; (iii) the two cell types have different dynamics of IL-2
production, proliferation and death.
Results
The type of responder T cell has the greatest impact in a
T-cell suppression assay
CD4
+CD25
-, CD4
+CD25
low and CD4
+CD25
high T cells were
isolated from human PBMC by flow sorting (Figure 1A). Using
FACS, the purity of these isolated cells was analyzed further for
CD25 expression (Figure 1A), proliferation (Figure 1B) and
intracellular Foxp3 expression (Figure 1C). Foxp3 is usually used
as a marker for recognition of Tregs, however, we measured its
intracellular presence in all three cell types. FACS-isolated
CD4+CD25- and CD4+CD25
low were treated further as separate
responder T cell subsets. We looked at the expression of different
surface markers and measured cytokines produced by the two
Figure 1. Isolation of human CD4
+CD25
high and CD4
+CD25
low T cells from PBMC. A) Purified human CD4 T cells were stained with PE-Cy5-
conjugated anti-human CD4, anti-human CD25-PE and FITC-conjugated anti-human antibodies for CD14, CD32, CD-116 and CD8. CD4
+CD25
high,
CD4
+CD25
low and CD4
+CD25
- T cells were then isolated excluding large activated lymphocytes and FITC-stained cells. Purity of FACS-isolated three T
cell subsets after the isolation is shown. Tregs purity was regularly .97%, while the purity for other two subsets was .94%. B) In vitro proliferation of
cell cultures presented. Proliferation of CD25
low T cells was significantly higher compared to the proliferation of CD25- (t-test, p=0.003).
C) Intracellular Foxp3 staining in three FACS-isolated cell subsets.
doi:10.1371/journal.pone.0015154.g001
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CD4
+CD25
low T cells showed activated phenotype, significantly
lower expression of CD45RA (Mann-U-Whitney test, p=0.0022)
and significantly higher expression of CD45RO (p=0.002)
(Figure 2A). In addition, significantly more CD4
+CD25
low T cells
expressed HLA DR and CD69 compared to CD4+CD25- T cells
(Mann-U-Whitney test, p=0.038 and p=0.0048, respectively).
Expression of HLA DQ showed borderline significance also in
favor of CD4+CD25
low compared to CD4+CD25- T cells
(p=0.057). CD4
+CD25
low T cells produced significantly more
IFN-gamma and IL-2 compared to CD4+CD25- T cells even after
mild stimulation provided by anti-human CD3-coated beads
(1 mg/ml) (Mann-U-Whitney test, p=0.015 and p=0.027,
respectively, Figure 2B), as well as for IL-10 (data not shown).
Both CD4
+CD25
- and CD4
+CD25
low responder T cells were
cultured either in the presence or absence of Tregs following 18
separate stimuli (Table 1). The percentage of suppression,
averaged over six individual measurements, was plotted as a radar
chart to accommodate all the data points (Figure 3A). The
percentage of suppression increases with the distance from the
center. Using a generalized linear model (GLM), neither the type
or number of APC nor time in culture were shown to influence the
extent of suppression, even though the strength of TCR
stimulation almost reached statistical significance (p=0.057).
However, the difference in suppression between CD25- and
CD25
low was highly significant, indicating that the type of
responder T cell was found to be the major predictor variable
for percentage of suppression (p=0.003, n=6 subjects, by GLM).
Assays with CD4
+CD25
low T cells as responders generally gave
lower suppression values than assays with CD4
+CD25
- T cells
(radar chart, Figure 3A). This highlights an intrinsic difference
between the two types of responder T cells. For subsequent
experiments, we used 1 mg anti-human CD3-coated beads, 1 x
irrPBMC and cultures cells for 3 days (* in Figure 3A). Although
few other conditions gave a substantial difference in suppression
between the two responder T cell subsets as well, the chosen
conditions were considered optimal as both responder T cell
subsets show the most consistent suppression results with the
lowest s.e.m. amongst the 18 different treatments for each of the
responder T cell subsets. The corresponding cpm values for these
specific optimal conditions are presented in Figure 3B and
corresponding percentage of suppression in Figure 3C. In
addition, this combination of stimuli was used for T cells isolated
from both healthy control and T1D-related subject groups
(Figure 6).
CD4
+CD25
low T cells proliferate more than CD4
+CD25
- T
cells
The proliferation profiles of the CD4
+CD25
- and CD4
+CD25
low
responders were assessed both in single and co-culture. Responder
T cells were labeled with CFSE and cultured alone and with Tregs
in the presence of 1 mg anti-human CD3 beads and 1xirrPBMC for
3 days. CFSE-labeled responder T cells were gated from other cells
in the culture and analyzed for cell division. We found that
CD4
+CD25
low responder T cells divided more than CD4
+CD25
- T
cells in both single culture and co-culture (Figure 4A). The
normalized mean number of divisions (40) for CD4
+CD25
- T cells
in single and co-culture were 0.7360.19 and 0.1660.04 respec-
tively, whereas for CD4
+CD25
low T cells the corresponding
values were 1.1260.2 and 0.560.07. These results show that
CD4
+CD25
lowTcellsdivided,1.5timesmore insingle cultureand
3 times more in co-culture compared to CD4
+CD25
- T cells. The
ratio of mitotic divisions in co-culture versus single culture is
0.2360.05 for CD4
+CD25
- T cells and 0.4660.06 for
CD4
+CD25
low T cells (Figure 4B, p,0.05, n=3).
Different kinetics of IL-2 production in CD4+CD25- and
CD4+CD25
low T cells
Counts per minute at three different time points were used to
record the distinct proliferation of the two responder T-cell subsets
on the stimulation. CD4+CD25- T cells proliferated significantly
Figure 2. Analysis of surface molecules and cytokine production by sorted T cells. Presented are median values for expression of A) surface
molecules and production of B) cytokines in both CD4+CD25- and CD4
+CD25
low T cells. Aliquots were incubated with appropriate flurochorome-
tagged antibody for surface markers CD45RA, CD45RO, CD62L, HLA DR, CD69 and HLA DQand analyzed by FACS (n=6). Statistically significant
difference in expression was reached for CD45RA, CD45RO, HLA DR and CD69 (Mann-U-Whitney test, p=0.0022, p=0.0022, p=0.038 and p=0.0048,
respectively). The cytokine production in CD4+CD25- was significantly lower for IL-2 and IFN-c compared to CD4
+CD25
low T cell production of the
same cytokines (p=0.027 and p=0.015, respectively, n=6). CD4
+CD25
low and CD4
+CD25
- T cells were cultured with 1 mg anti-human CD3 beads and
1xirradiated PBMC for 48 hours. Cytokines were measured using CBA assay. * - p,0.05; ** - p,0.005.
doi:10.1371/journal.pone.0015154.g002
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lowT cellsat alltime points(p,0.05 at
24 hours and p,0.01 at later time points, Figure 5A). We also
measured % of dead cells in single and co-culture at three time
points during culturing of both responder T cell subsets (Figure 5B).
CD4+CD25- were dying at slightly higher rate in single culture
compared to CD4+CD25
low T cells during the first 48 hours, which
changed at 72 hours. In co-culture, the faster death rate of
CD4+CD25- T cells at 24 hours compared to CD4+CD25
low
flipped at 48 and 72 hours, when CD4+CD25
low started dying
faster (Figure 5B). Since it has been reported that IL-2 is directly
involved in the proliferation of responder T cells [23] and that
human Tregs are dependent on available IL-2 for their suppressor
activity [24], we monitored IL-2 production in both responder T-
cell subsets at 4 different time points. This was done using RT-PCR
(Figure 5C). CD4+CD25
low T cells responded by transcribing IL-2
mRNA faster/sooner than CD4+CD25- T cells. At 8 hours
CD4+CD25
low T cells showed .2 fold increase in IL-2 mRNA
productioncomparedtoCD4+CD25-Tcells(t-test,p=0.02).At20
and 48 hours, IL-2 mRNA production in CD4+CD25- was higher
than in CD4+CD25
low T cells at the same time points. However, at
the last measured time point (72 hours), CD4+CD25
low T cells
increased IL-2 expression almost 2 fold compared to CD4+CD25-
T cells reaching significance again (t-test, p=0.038). This can be
explained by bimodal pattern of IL-2 expression in CD4+CD25
low
T cells. Namely, CD4+CD25
low T cells express IL-2 sooner,
proliferate faster, and start dying later. CD4+CD25
low T cells that
survive begin rapid IL-2 production and proliferation, while
CD4+CD25- T cells responded at a slower rate. Furthermore,
proliferation and suppression of both T cell responder subsets under
different concentrations of recombinant IL-2 or anti-human IL-2
was also recorded. Addition of 20 IU/ml of recombinant IL-2 to
both single and co-culture of CD4+CD25- responder T cells was
able to produce the same proliferation ratio between single and co-
culture as seen in CD4+CD25
low T cells without exogenous IL-2
(Figure 5D). When single and co-cultured CD4+CD25
low T cells
were treated with different concentrations of anti-human IL-2, the
proliferation ratio, seen in single and co-cultured CD4+CD25-, was
Figure 3. CD4
+CD25
low T cells were suppressed less than CD4
+CD25- in in vitro co-culture with Tregs. A) The percentage of suppression
for CD4
+CD25- (blue, outer line) and CD4
+CD25
low T cells (red, inner line) as responders in co-culture with Treg (Tresponder:Treg = 1:1) for 3 or 5 days
with 18 different combinations of stimuli. The suppression difference is most statistically significant when the type of responder T cells differ
(p,0.003, n=6) irrespective of type of APC or duration and strength of stimuli. Asterisk (*) indicates conditions chosen for experiments that followed.
B) Presented are cpm and standard errors for conditions with asterisk in Figure 3A. C) Percentages of suppression for conditions shown with asterix in
Figure 3A are presented.
doi:10.1371/journal.pone.0015154.g003
Table 1. Tested variables in in vitro human suppression assay.
APC
Strength of
stimulation
Time in
culture
CD4+CD25- or
CD4+CD25
low
1xPBMC 0.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
1 mg.ml anti-human
CD3-coated beads
3 days
5 days
2.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
4xPBMC 0.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
1 mg.ml anti-human
CD3-coated beads
3 days
5 days
2.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
4xTdAC 0.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
1 mg.ml anti-human
CD3-coated beads
3 days
5 days
2.5 mg.ml anti-human
CD3-coated beads
3 days
5 days
doi:10.1371/journal.pone.0015154.t001
CD4+CD25- and CD4+CD25low As Responder T-Cells
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15154CD4+CD25- and CD4+CD25low As Responder T-Cells
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15154achieved with 3 mg/ml of anti-human IL-2 (Figure 5E). Thus, we
were able to reconstitute the observed proliferation differences
between single culture and co-cultures for the alternative responder
T cells by addition of recombinant IL-2 to CD25- assays or by
deprivation of IL-2 in CD25
low assays. These experiments confirm
existing differences in kinetics of IL-2 production between
CD4+CD25- and CD4+CD25
low T cells. It should be noted that
experimental conditions were slightly changed because of potential
changesin viability. Thus,in this series of experiments with addition
of IL-2 and anti-IL-2 cells were in culture 54 hours, pulsed and left
in culture for additional 15 hours (totaling 70 hours).
CD4+CD25
low T cells are harder to suppress in T1D-
related subjects
The optimal suppression assay (asterix in Figure 3) was then
applied to our cohort population. The only difference from the
assay developed on anonymous leukopacks was the ratio between
Tregs and responders, which we further optimized (Figure S1) due
to limited number of available FACS-isolated Tregs from pediatric
subjects. The optimal ratio was determined to be 1:10. This ratio
was then used for measurement of Treg function across subject
groups. Such high ratio additionally indicated purity of the Treg
subset. There was statistically significant difference in suppressive
Figure 4. CD4
+CD25
low responder T cells proliferate faster and are harder to suppress. A) CFSE-labeled responder T cells were cultured for
3 days with 1 mg/ml anti-human CD3-coated beads and 1x irradiated PBMC either in the presence or absence of an equal number of Tregs. Each color
represents a particular cell generation. Blue color (first peak from right on all four histograms) presents undivided cells. Orange color presents cells
that divided once, green peak cells that divided twice, purple color cells that divided three times and light blue presents cells that divided four times.
This is representative of three independent experiments. B) The ratio of the normalized mean number of division in co-culture/single culture was
calculated using the software ModFit and method of De Boer and Perelson (see Statistical analysis). The average ratio of mitotic divisions for three
samples in co-culture versus single culture is 0.2360.05 for CD4
+CD25
- T cells and 0.4660.06 for CD4
+CD25
low T cells (p,0.05, n=3).
doi:10.1371/journal.pone.0015154.g004
Figure 5. Time-course experiment showed different dynamic of proliferation, death and IL2-production in CD4+CD25- and
CD4+CD25
low T-cells. A) CD4+CD25
low proliferated more rapidly than CD4+CD25- T cells. At indicated bars (* and **) both single and co-cultures of
CD4+CD25
low had significantly higher cpm (*p,0.05 and ** p,0.01, respectively) compared to CD4+CD25- T-cell single and co-cultures. B) Single and
co-cultures were harvested, washed and stained with 7AAD before acquiring. CD4+CD25- T cells were dying at a slightly faster rate at the earlier time
points in both single and co-cultures versus at later time points. Mean values of three samples are presented. Borderline significance was detected
between the two responders for their co-cultures after 24 hours time point and for single cultures at 72 hours (p=0.05 and p=0.08, respectively). C)
CFSE-labeled responder T cells were stimulated, harvested, FACS sorted as CFSE-positive cells and stored in Trizol at 280uC without APC and other
cells present in cultures, until RNA was isolated and real-time RT-PCR performed. IL-2 production was higher in CD4+CD25
low T cells at earlier time
point (8 hours), compared to CD4+CD25- T cells. However, at later time points (20 and 48 hours), CD4+CD25- showed higher IL-2 production
compared to CD4+CD25
low T cells, which switched back again to CD4+CD25
low T cells at 72 hours. Mean values of three samples are presented. D)
Addition of 20 IU/ml of recombinant IL-2 to CD4+CD25- T cells cultures caused similar ratio single/co-culture proliferation as detected in
CD4+CD25
low T-cells after 3 days of in vitro stimulation (CD4+CD25
low are presented in the first column for comparison). This is one of 2 separate
experiments with similar results. E) Addition of 3.5 mg/ml of neutralizing, anti-human IL-2 was needed in CD4+CD25
low cultures to cause similar ratio
of single/co-culture proliferation as the one recorded in CD4+CD25- T cells (CD4+CD25- are presented in the first column for comparison). This is one
of 2 separate experiments with similar results.
doi:10.1371/journal.pone.0015154.g005
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(RO) T1D and aAb+ve subjects (Kruskal-Wallis test, p=0.012).
However, the difference was even more pronounced for
CD4+CD25
low T cells (Kruskal-Wallis test, p=0.0001). In healthy
control subjects (n=14), Tregs showed lower suppressive potential
of CD4+CD25
low compared to CD4+CD25- T cells (37.667.2 vs
50.267.3%, p=0.017, Figure 6B vs. 6A), corroborating results
generated with leukopacks. The difference in suppression of
CD4+CD25
low and CD4+CD25- was also significantly differed in
both RO T1D subjects (222.269.6 vs. 17.865.5, respectively,
p=0.0025, n=11, Figure 6B vs 6A) and in aAb-positive subjects
(9.968.0 vs. 32.068.1%, respectively, p=0.008, n=12, Figure 6B
vs 6A). Control of CD4+CD25
low T cells proliferation was,
therefore, decreased in all three groups, but, seriously compro-
mised only in RO T1D subjects (Kruskal-Wallis test, p=0.0001,
Figure 6B).
Discussion
In organ-specific autoimmune disease, the affected organ is
largely infiltrated with T lymphocytes by specific homing. At the
site, further activation, proliferation, survival and effector function
of autoreactive T cells results in tissue damage. It is likely that the
autoreactive T cells belong to CD4
+CD25
low T cell population.
Tregs are known to regulate these activated T cells, thereby
inhibiting their effector function. Although both in vitro and in vivo
regulation of these autoreactive T cells by Tregs has been studied
in animal models for many autoimmune diseases, fewer human in
vitro studies have been performed. Studies exploring
CD4
+CD25
low T cells as responders in human in vitro suppression
assays are scarce [25,26]. The majority of studies were performed
with either naı ¨ve CD4
+CD25
- T cells or PBMCs as responders. It
has been acknowledged that difference between naı ¨ve and
activated cells exist, as several studies have shown that
CD4
+CD25
low T cells have a different activation status than in
vitro-activated naı ¨ve T cells [27,28,29,30,31]. Naive T cells, once
activated, proliferate and differentiate into effector T cells that
differ from naive cells with respect to faster kinetics of their
response to re-stimulation. In addition, activated cells are less
dependent on co-stimulation in exerting their effector function
(cytokine production, migration, proliferation) [32]. In the present
study we set out to explore in-vitro suppression exercised by FACS-
isolated Tregs on two types of human responder T cells: naı ¨ve,
CD4+CD25- and in vivo activated, CD4+CD25
low T cells.
The strength of stimuli in co-culture with Tregs dictates whether
suppression will occur or not. With high TCR stimulation,
suppression is either low or abrogated [33]. When the 18 different
stimuli were examined, irrespective of the strength of TCR signal
or number and types of irradiated APC cells used in co-culture, the
strongest statistical difference in suppression we found to be
explained by the type of responder T cells (p,0.003). The strength
of TCR signal used in this study had some, rather weak, effect on
suppression (p,0.057). Based on these results, we can conclude
that the type (nature) of the responder T cells has the greatest
impact on suppression assay.
Maintenance of T cell homeostasis is critical in the well-
orchestrated immune system and Tregs are one of the key players.
They depend on IL-2 produced by other T cells for their
development, proliferation and efficient function [34]. One of the
indicators of suppression by Tregs is the inhibition of transcription
of this proliferative cytokine in responder T cells [35]. Differential
suppression of CD4
+CD25
- and CD4
+CD25
low responders by the
same Tregs could be due to an unequal inhibition of IL-2
transcript in the two responder T cells. As CD4+CD25
low T cells
have already been activated, they react faster than naı ¨ve T cells on
the same stimulus. Our results showed that CD4
+CD25
- and
CD4
+CD25
low responder T cells produced different amounts of
IL-2 mRNA as well as IL-4 (data not shown). In vitro stimulated,
CFSE-positive CD4
+CD25
low responder T cells began IL-2
production earlier than CD25-, suggesting different kinetics
between the two responder T cells [32]. IL-2 production decreased
up to 48 hours in culture, while death rate increased (Figure 5).
However, at 72 hours in culture, CD4
+CD25
low responder T cells
that survived began a new cycle of IL-2 production and
proliferation. This could be explained by bimodal IL-2 expression
hypothesis [36]. Bimodal IL-2 expression could be achieved
through positive feedback loops of upregulated IL-2R alfa [37],
which is differently expressed in CD4+CD25- and CD4+CD25
low
T cells. In addition, it has been reported that NFATc2
transcription factor, shown as powerful molecular switch of IL-2
expression, shows a bimodal expression [38].
Another possible explanation for reduced suppression of
CD4
+CD25
low responder T cells is that with further activation,
the pre-activation status of these cells make them divide more
easily compared to CD4
+CD25
- T cells. The proliferation profile
of CFSE-labeled responder T cells under the same stimuli
(Figure 4) showed that CD4
+CD25
low T cells divide significantly
Figure 6. RO-T1D and aAb+ve unaffected subjects show dramatic decrease in suppression of CD4+CD25
low-Tcell proliferation by
Tregs. There was statistically significant difference in suppressive potential of CD4+CD25- T cells between control, RO T1D and aAb+ve subjects
(Kruskal-Wallis test, p=0.014, Figure 6A). However, the difference was even more pronounced with CD4+CD25
low as responder T cells (Kruskal-Wallis
test, p=0.0007, Figure 6B). Both RO T1D and autoantibody-positive subjects showed significant decrease in suppression of CD4+CD25
low T cells
(paired t-test, p=0.0025 and p=0.008) compared with their respective CD4+CD25- T cells. In addition, there was significant difference in suppression
of the two responder T cells in healthy control subjects (p=0.017).
doi:10.1371/journal.pone.0015154.g006
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+CD25
- T cells. The increased
proliferation of CD4
+CD25
low T cells may play a role in vivo and
explain the existence of this expanded T-cell subset in autoim-
mune disease patients [39,40]. Several autoimmune patient studies
showed that CD4
+CD25
low T cells expressed increased levels of
several surface molecules like CD95 [41], CD71 [42,43], CD26
[27], CD29 [43] and CD28 [44]. These studies clearly indicate
that CD4
+CD25
low T cells from autoimmune patients are different
from in vitro activated naı ¨ve-T cells and emphasize the importance
of using in vivo activated T cells (CD4
+CD25
low) as responders in in
vitro suppression studies. Our results presented in Figure 6 show
significant decrease in control of CD4+CD25- T cell proliferation
by Tregs isolated from RO T1D subjects, as we showed earlier
[45]. In the present study we show that this decrease was even
more prominent with CD4+CD25
low T cells as responders. In
aAb-positive subjects, there was a clear difference in suppressive
potential of CD4+CD25- compared to CD4
+CD25
low T cells,
which could offer an explanation for impaired sensitivity of
responder T cells to the suppressive effect of Tregs in autoimmune
diseases reported by increasing number of studies [15,16,17,46].
The role of IL-2 is essential for Treg function. Therefore the local
cytokine milieu that depends on the activation status of effector T
cells, has crucial role on Treg function. Here we showed that our
optimized in vitro suppression assay, if set up with both naı ¨ve and in
vivo activated T cells as responders, can identify inability of Tregs
to control activated T cell proliferation before symptoms of
autoimmune disease appear.
Although the generated results were consistent, it should be
noted that the isolation of Tregs was performed based on CD25
expression, a surface marker that is not unique to Tregs. However,
there is no unique human surface marker to date that would
distinguish Tregs from non-regulatory T cells. FACS isolation
based on CD25 and CD127 (and especially solely based on
CD127) did not show higher suppressive potential in our hands
compared to CD4CD25
high T cells (data not shown). Other groups
have also reported on the unclear advantage of isolation based on
CD127/CD25 compared to the use of CD25 [47,48,49]. Despite
the impurity of Tregs, our results show divergence between the
two responder cells, clearly pointing to differences in the two types
of cellular interaction that occurs in co-culture.
In summary, based on extensive study presented here, we
concluded that human in vivo activated T cells and naı ¨ve T cells
behave differently in in vitro suppression assays when set up with
natural Tregs. The type of responder cells is an important variable
of suppression assay, which can explain resistance to regulatory T
cell-mediated suppression noticed by several groups. The
increased production of IL-2 by CD4
+CD25
low T cells might
explain the observed differences in suppression. We show that the
use of this in vitro suppression assay with both naı ¨ve and in vivo-
activated T cells as responders is an excellent tool in the
recognition of an early state in immune imbalance. Further
investigation into the pleiotropic nature of suppression with
different responder T cells in T1D and other autoimmune diseases
may give more insight into Tregs function in diseased conditions.
Materials and Methods
Media, reagents and antibodies
Anti-human CD4-PE-Cy5, anti-human CD25-PE (M-A251),
anti-human CD14-FITC, anti-human CD32-FITC, anti-hu-
manCD116-FITC, anti-human CD8-FITC, anti-human CD28
(CD28.2) and Human Th1/Th2 cytokine cytometric bead array
(CBA) kit were purchased from BD Bioscience, CA. L-glutamine,
sodium pyruvate, HEPES, penicillin/streptomycin were pur-
chased from Life Technologies, MD. Anti-human CD3 (UCHT1)
was purchased from Ancell, MN. Anti-human CD4 microbeads
and anti-human CD2-magnetic beads were purchased from
Miltenyl Biotech, CA. Tosylactivated magnetic beads used for
coating with anti-human CD3 were purchased from Dynal
Biotech (Norway) and the procedure was done according to
manufacturer’s protocol using 0.5 mg, 1 mg and 2.5 mg anti-human
CD3 per 10
7 beads for coating. Human AB serum was purchased
from Atlanta Biologicals, GA. RPMI 1640 was purchased from
BioWhittaker, MD. Human recombinant IL-2 was purchased
from BD Biosciences and anti-human IL-2 from R&D Systems.
Cell isolation
PBMC were isolated from human leukopacks (n=6) kindly
provided by the Blood Center of Wisconsin, Milwaukee by Ficoll-
Hypaque (Amersham Pharmacia Biotech, NJ) density gradient
centrifugation. The CD4+ T cells were isolated from 9–10610
8
PBMC by MACS sorting using anti-human CD4 microbeads. The
isolated CD4+ (1–2610
8) T cells were stained for FACS isolation
as decribed earlier [45]. PBMC from T1D-related subject groups
did not undergo MACS sorting, they were directly stained for
FACS isolation. Gates for CD4
+CD25
low were made based on
Fluorochrome Minus One. Gating and purity of isolated cells is
presented in Figure 1a. T cell-depleted accessory cells (TdAc) were
isolated by negative selection of PBMC incubated with anti-
human CD2-coated beads (Miltenyl Biotech, CA) followed by
MACS sorting.
Human subjects
Thirty seven subjects were ascertained primarily through the
diabetes clinic at Children’s Hospital of Wisconsin (CHW).
Inclusion criteria for control subjects were a random blood
glucose ,110 mg/dl, no personal and family history of type 1
diabetes and an absence of diabetes-specific autoantibodies (to
GAD, insulin and IA-2). Diabetes was defined according to
accepted criteria: 1. Symptoms of diabetes plus casual plasma
glucose concentration §200 mg/dl (11.1 mmol/l) OR 2. FPG
§126 mg/dl (7.0 mmol/l). The protocol was approved by the
CHW institutional review board (IRB) and participants and/or
their parents (guardians) provided written informed consent and
completed a questionnaire. All subjects had T1D-specific autoan-
tibodies measured at the recruitment visit. (Table S1 presents the
demographic data).
Cell culture
Both CD4
+CD25
- and CD4
+CD25
low (10
4 cells/well) were
cultured in RPMI 1640 media supplemented with 2 mM L-
glutamine, 5 mM HEPES, 100 U/ml penicillin/streptomycin,
0.5 mM sodium pyruvate and 10% human AB serum. Cells were
stimulated with anti-human CD3 coated beads (0.5, 1, 2.5 mg, 3
beads/cell) in U-bottom 96 well plates (Costar, NY) in the
presence of three variations of autologous irradiated APC: 4 x
PBMC, 4 x TdAc or 1 x PBMC for 3 or 5 days. Irradiation was
performed at dose of 5000rad. For the suppression assays, Treg
cells were co-cultured with CD4
+CD25
- or CD4
+CD25
low at a 1:1
ratio (Treg:Tresponder). At the end of the culture (3 or 5 days),
cells were pulsed with 1 mCi of [
3H]thymidine (Amersham
Pharmacia Biotech, NJ) and harvested after 16 hours. The cpms
per well were determined using a scintillation counter (Top Count
NXT, Packard, CT). However, in experiments with added IL-2
and anti-IL-2, cells were culture for 54 hours (because of
anticipated changes in viability), pulsed and cultured for another
16 hours.
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CFSE is a vital stain which, upon entering cells, undergoes
esterase cleavage and diffuses throughout the cytoplasm. As cells
divide, the CFSE is split equally between the daughter cells
resulting in diminished CFSE signal detection in flow-cytometric
analysis. CFSE was added at a final concentration of 125 nM to
1–2610
6/ml of responder T cells and incubated for 15 minutes at
room temperature in the dark. The reaction was stopped by
adding an equal volume of cold media containing 10% serum and
the cells were washed twice with the same media. CFSE-labeled
responder T cells were only analyzed for 3 days since by 5 days
fractions of responders could not be distinguished from unstained
cells. Analysis of divisions of responder T cells was done using the
ModFit software (Verity Software House, USA).
Mortality assay
After 3 days of culture, cells were washed and stained with 7-
aminoactinomycin D (7AAD) and analyzed by Flow Cytometry.
The population stained with 7AAD has been found to correspond
to dead cells. Responder cells in both single and co-culture were
assessed for death. The percentage of increase in death in co-
culture is X= [Ac-As]/As x 100, where As = dead cells in single
culture, Ac = dead cells in co-culture.
Flow cytometry
For all flow-cytometric analyses, cells were stained with the
appropriate combination of monoclonal antibodies in PBS
containing 0.5% BSA and 2 mM EDTA for 20 minutes at 4uC.
After washing, the labeled cells were analyzed or fixed with 2%
paraformaldehyde, then analyzed using a FACS Calibur with
CellQuest or FACSDIVA software. Cytokines were measured
from cell culture supernatants after 48 hours of stimulation (1 mg
anti-human CD3 beads and 1 x irrPBMC) with CBA assay kit
according to manufacturer’s protocol (BD Bioscience). Foxp3
expression was measured by Flow Cytometry using intracellular
Foxp3 staining kit from eBioscience, USA.
RT–PCR
Total cellular RNA was extracted from the sorted CFSE-labeled
responder cells after 24, 48 and 72 hours in culture with Trizol
reagent. Total RNA was processed as described earlier [50]. The
primer sequences were as follows; IL-2: 59-CAGTGCACC-
TACTTCAAGTTCTACA-39 and 59-CCTGGTGAGTTTGG-
GATTCTTGTAA-39. The fold change of IL-2 mRNA has been
calculated using the following formula. Fold Change =2
-DCT,
where DCT = CT
IL-2 -CT
GAPDH. Percentage reduction in IL-2
mRNA expression from single to co-culture is [(Xs-Xc)/Xs] x 100,
where Xs = fold change of IL-2 in single culture, Xc = fold
change of IL-2 in co-culture.
Time-course experiment
Separate plates were set up with CFSE-stained both
CD4+CD25- and CD4+CD25
low T cells as responders that were
isolated from additional leukopacks. Cells were collected at
24+16 hours, 48+16 hours and 72+16 hours, stained with 7AAD,
acquired for analysis and the rest was sorted as CFSE+ve cells on
FACSVantage or FACS Aria to eliminate Tregs, irradiated PBMC
(5000 rad) and anti-human CD3-coated beads. FACS-sorted
responder T cells were put in Trizol and kept at -80uC until RNA
isolation was performed. At each time point, supernatants were
taken out from wells after which they were pulsed for measuring of
3H-thymidine incorporation. Supernatants were kept at -80uC until
cytokine measurement using CBA assay was performed.
Cytokine measurement
Measurement of cytokine levels was performed using the
Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit
(BD Biosciences). Supernatants were thawed and 50 ml was used
for simultaneous measurement of following cytokines: INF-g,
TNF-a, IL-5, IL-4 and IL-2. The assay was performed according
to the manufacturer’s protocol. The samples were acquired on a
FACSCalibur (BD Biosciences) following the cytometer setup
protocol. The FACS data was analyzed using the CBA 6 bead
analysis software (BD Biosciences).
Statistical analysis
We employed a generalized linear model (GLM) with the
dependent variable being the percentage suppression [(s-c)/s] x
100%, where s=cpm in single culture and c=cpm in co-culture.
The factors were strength of stimulation (three levels, 0.5, 1 and
2 mg/ml anti-CD3 coated beads), type and amount of irradiated
APC (1X PBMC, 4X PBMC and 4X TdAC), days of co-culture (3
or 5 days) and type of responder T cells (CD4
+CD25
- or
CD4
+CD25
low T cells). An analysis of variance was performed.
From the CFSE data the numbers of cells in each generation
were calculated using the software ModFit. The normalized mean
number of division that cells have undergone was calculated using
method of De Boer and Perelson, where Xn(t) = the number of
cells undergone n divisions by time t [51]. Since after n divisions,
each cell gave rise to a maximum 2
n progeny under ideal
conditions, Xn t ðÞ 2{n = (is) the number of precursors that would
have generated Xn(t) cells. Total number of cell division that Xn(t)
cells have undergone is expressed as nXn t ðÞ 2{n. So, the number of
precursors that would have generated all the current cell
population is
P ?
n~0
Xn t ðÞ 2{n and the total number of cell divisions
for the entire current cell population is
P ?
n~0
nXn t ðÞ 2{n. The
normalized mean number of division cells have undergone is
hence, m t ðÞ ~
P ?
n~0
nXn t ðÞ 2{n=
P ?
n~0
Xn t ðÞ 2{n.
Supporting Information
Figure S1 Titration of responder T cells in suppression
assay. CD4+CD25- were FACS isolated from leukopacks drawn
from healthy volunteers and cells were stimulated with 1 mg/ml
anti-human CD3 with 1x irradiated PBMC as APC for 3 days.
Since extent of suppression began decreasing at 1:16 ratio, 1:10
was consistently performed in experiments with T1D-relevant
subject groups.
(TIF)
Table S1 Demographic data for T1D-related subject groups
(DOC)
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